Introduction
Clinical trial site selection is a critical factor that significantly impacts the success of a trial. It encompasses considerations such as patient recruitment, data quality, and adherence to timelines. The integration of electronic health records (EHR) in trials has shown immense potential, but it requires careful planning and coordination to achieve effective results.
In addition, the modernization of platforms like ClinicalTrials.gov reflects the industry’s commitment to improving user engagement and operational efficiency. This article explores the challenges and importance of site selection in clinical trials, with a particular focus on Latin America. It highlights the complexities of conducting trials in this region due to cultural, linguistic, and logistical hurdles.
The article also discusses real-world case studies and offers recommendations for future trials in Latin America. Overall, the article underscores the need for strategic and inclusive site selection in clinical trials to ensure accurate data collection and successful outcomes.
Background
The intricacies of clinical trial site selection are paramount to the trial’s outcomes, particularly in terms of , quality of data, and adherence to projected timelines. It is well-understood that possess the potential to revolutionize trials; however, integrating EHR-sourced data into existing trial infrastructures requires deeper consideration to meet study objectives effectively.
A notable demonstration project illustrated precisely how EHR data supplemented the information gathered in a multi-center pharmaceutical industry outcomes trial, providing a prime example of the successful orchestration of technological and operational resources. This integration was facilitated by a , which handled complexities, including technical, governance, and operational challenges.
Furthermore, the ongoing modernization of ClinicalTrials.gov signals an industry-wide embrace of technology to enhance user engagement and operational efficiency. The imminent consolidation into a single, modernized platform reflects the importance of adopting an intuitive, scalable, and user-centric approach in .
This direction towards modernization is mirrored in industry experiences, including those of practitioners with extensive backgrounds in medical devices and regulated environments. Lessons from a multitude of clinical studies emphasize the substantial impact of nuanced planning and decision-making, often years in advance of a study’s conclusion. Analyzing numerous data points has led to insights on optimizing every decision for the greatest benefit over the long term, akin to strengthening each link of a chain to bear the weight of eventual outcomes.
Additionally, the dialogue on patient-centricity has taken center stage, advocating for in trial planning. Addressing the logistical challenges faced by patients notably in accessing abroad, emphasizes the need for a compassionate and inclusive approach that accommodates a wide demographic.
A commitment to is also crucial, as it recognizes the varying impacts of diseases across racial, ethnic, age, sex, and sexual orientations. This enlightenment signals a pioneering shift in designing that speaks volumes about the industry’s dedication to evolving its methodologies to be more reflective of the populations they aim to serve.
Importance of Site Selection in Clinical Trials
Selecting the optimal site for is a crucible that determines its efficiency and efficacy. With the rise of , it’s clear that existing infrastructures and sites must be adeptly leveraged to fulfill study objectives. A prime example of this was observed in a demonstration project where EHR data supplemented multi-center pharmaceutical industry outcomes trial data.
Furthermore, the complexity of trial designs, such as the R-RCT employed in the DAPA-MI study, demonstrates the innovative blending of registry and randomized control methodologies to enhance patient enrolment and maintain scientific clarity. The outcomes underscore the vital role of and infrastructure in underpinning operational success and .
Contemporary frequently utilize technology to both expedite results gathering and to boost data accuracy. Real-time patient monitoring using digital tools and wearable tech, as well as extensive use of EHRs, speaks volumes about how central coordination can influence overall trial outcomes. A pertinent example is seen in the DAPA-MI trial, where an expected low count of primary composite outcomes prompted a revaluation of study endpoints, showcasing the adaptability required during these studies.
Evidence indicates that trial durations have been extending, escalated by pressures to be first in a competitive market. In the past decade, Phase 3 trials have lengthened on average from 41 to 44 months and Phase 2 trials from 37 to 41 months. Unfortunately, up to 80 percent of fail to conclude as scheduled, underlining the severity of the challenge faced by sites expected to operate efficiently while adhering to .
Delays in , protocol deviations, and compromised are often the results of suboptimal . The recent leadership turmoil at INVIMA, Colombia’s regulatory authority, and the ‘horrendous’ conditions described in Brazil’s medicine-related databases both serve as reminders of the unpredictable regulatory environments that can affect the suitability of trial sites in Latin America.
Amid such uncertainties, the call for practical use of EHR in echoes louder. As revealed by the Flatiron Health and the FDA’s collaboration, the definition of quality for real-world data (RWD) remains a crucial concern, challenging standardization and consistency across health agencies.
Challenges in Site Selection in Latin America
Conducting presents a multifaceted set of challenges, particularly during the . To effectively manage this critical step, investigators must comprehend and adeptly navigate the region’s intricate . Unique obstacles such as cultural variances, , and assorted logistical hurdles further compound the complexity of launching .
Latin America’s reliance on mining and its socio-economic framework significantly influence the clinical trial milieu, echoing the need for comprehensive information and transparency in operationalizing clinical sites—a process often impeded by fragmented knowledge dissemination and regulatory convolutions.
Evidence reflects a direct correlation between mining activities and higher living standards, although safety and health detriments remain a stark reality. Integrating the insights gleaned from the recent appointment uncertainties of potential regulatory leaders in Colombia, we envision that could ostensibly impact site selections and subsequent trial procedures. Aligned with global , it is crucial to mirror DCT principles by initiating studies that are accessible to participants, upholding data integrity and protecting privacy.
Training expansion and enhanced pharmacovigilance reported by Honduras’s Sanitary Regulatory Agency (ARSA) exemplify proactive strides toward fostering a robust clinical trial environment. Advocates argue for the imperative of streamlining administrative processes and eliminating obstructions to facilitate research that can catalyze pivotal healthcare advancements. Concurrently, advancements such as ANVISA’s implementation of digital means to augment medication usage comprehension hint at a broader digital transformation agenda that could simplify regulatory compliance and enhance clinical process logistics.
Case Study Overview
With a focus on Latin America, we delve into the intricate process of —a pivotal aspect that impacts the quality of . As evidenced by the Quality Evidence for The Transformation of Health Systems for Latin America and the Caribbean (Quest LAC) network, incorporating is vital in regions afflicted by subpar healthcare services, resulting in millions of preventable deaths annually.
The QuEST LAC network, comprising experts from countries including Peru, Argentina, and Mexico, underscores the urgency to foster research talent and elevate healthcare systems. It also emphasizes the dire need for that impacts society’s wellbeing and trust—highlighting the regional network’s role in shaping and disseminating healthcare standards.
Additionally, the recent between Dana-Farber Cancer Institute and Oncoclínicas & Co illustrates the commitment to adopting gold-standard practices in medical oncology. The inaugural Oncoclinicas Cancer Center in belo Horizonte shows the gravitas of high-quality site selection, with measures in place to ensure continuous improvement in patient care, reflecting a collaborative ethos that aligns with innovation and exceptional patient outcomes.
Furthermore, tackling healthcare challenges in the digital realm can lead to significant advancements, as demonstrated in Uruguay’s partnership with AGESIC to centralize and leverage digital health data—showing that strategic site selection extends beyond physical locales into the realm of data management and digital infrastructure.
This study proffers a comprehensive approach by examining real-world examples, such as the integration of technological advances in Uruguay’s health services, and the establishment of cancer care centers with elevated standards via international collaborations. These instances embody the best practices and are instructive for effectuating successful , ultimately forging pathways toward improving health outcomes across Latin America.
Methodology
To construct an insightful case study examining the pivotal role of in , we delved into a comprehensive literature review of existing research, publications, and industry standards with a focus on . The study further drew on insights from interviews with clinical research experts who possess specialized knowledge in overseeing trials within this region. Through meticulous analysis, we distilled the gathered intelligence to uncover prevalent patterns, encountered challenges, and strategies that have proven effective in .
The findings signpost critical issues in such as the overarching and low public investment in care, which considerably impact the selection and success of . The case highlights that bears 80% of the global disease burden, with mental illness and substance abuse disorders greatly contributing to the overall disease impact. Thus, there is an acute relevance for focusing on these areas, which aligns with our mission of enhancing in the region.
Furthermore, our analysis addressed the influence of external factors on and health policy that could affect , as illustrated by news reports such as the anticipated confirmation of a new head for INVIMA in Colombia and ANVISA’s setbacks in Brazil. We acknowledged the evolving regulatory landscape, training enhancements in pharmacovigilance, and the importance of making drug information accessible, as exemplified by Honduras’s ARSA reporting a 60% increase in inspections and the introduction of digital tools for medication labeling in Brazil.
In essence, this assessment not only draws from scholarly sources and professional experiences but also incorporates real-world events and data that shape trial environments. This comprehensive approach ensures a robust understanding of dynamics which is essential for optimizing across diverse n contexts.
Results
A practical example to consider is the for the establishment of offices by prominent entities such as Accenture, Teleperformance, and Astound Commerce. By seeking out metropolitan locales with ample population and developing infrastructure, these companies circumvent the saturated markets of Western and Northern Europe and Asia in favor of more cost-effective, scalable solutions. This same principle applies to the realm of , where become a linchpin in for .
Such alliances not only address language and cultural barriers but also allow for leveraging local knowledge, which is particularly salient in intrinsic to the region. As elucidated by the collaboration between the Icahn School of Medicine at Mount Sinai and the Brazilian Clinical Research Institute (BCRI), fostering international partnerships catalyzes advancements in medical research, underscoring the significance of establishing solid foundations in .
Technology, too, plays a pivotal role in optimizing processes. As embody a quintessential component in validating the safety and efficacy of medical interventions, utilizing data-driven approaches to scrutinize site performance metrics and patient demographics becomes instrumental. Moreover, reviewing historical trial data can be influential in , as it might influence both the quantity and quality of available trial participants.
Ultimately, by joining the rigors of , individuals contribute to the transformative changes in healthcare and patient treatment modalities that can resonate globally.
Discussion
Reflecting on in Latin America presents a dual opportunity: an examination of current practices and a discourse on the exigency for . The experience of Vida Plena, an advocate for improvements in Latin America, underscores the dire prevalence of disorders—where 80% of the disease burden falls on low- and middle-income countries. This is compounded by the economic ramifications of mental illnesses, manifested through reduced productivity and increased absenteeism, thus fueling a cycle of poverty that exacerbates these .
In alignment with Vida Plena’s findings, the landscape of conducting and early-feasibility studies in Latin America is nuanced with administrative and community-specific challenges. To navigate this terrain effectively, a proactive is imperative. As reiterated by industry professionals, impediments at the administrative level require keen foresight and adept handling, which is particularly critical across all research phases.
A paradigm shift towards better inclusion practices in is also essential to mirror the diverse populations afflicted by diseases such as Type 2 diabetes. Overcoming barriers to omics research within LMICs, through robust administrative, institutional, and project-specific strategies, is part of this broader narrative for inclusivity and .
The importance of fortifying such endeavors is echoed by ongoing discussions within the healthcare policy framework. One such case is the unexpected withdrawal of INVIMA’s expected head, citing procedural delays, which reflects the systemic issues that can hamper regulatory advancement. Moreover, the pause in Brazil’s controlled substance database reporting due to system instability presents another administrative hurdle directly affecting health regulatory functions.
Conversely, measures like Honduras’s ARSA expanding their pharmacovigilance efforts exemplify the potential for substantial progress through concerted action.
Addressing the scarcity of investment in regions like Latin America—where only a fraction of the healthcare budget is allocated to compared to other countries—stands as both a caution and a call to action. The disconnection between economic investment and the crisis only accentuates the necessity for a streamlined approach, ongoing education for investigators, and the utilization of inherent regional expertise to bridge the gap between evidence and clinical practice. The collective endeavors target not just the immediate challenges but also the overarching aim to promote robust and equitable healthcare throughout Latin America.
Recommendations for Future Trials
To advance the success of forthcoming , it is essential to assimilate key strategies shaped by . A paramount first step is to fortify alliances with local investigators and academic bodies. This enhanced are fundamental, as evidenced by 80% of the mental health disease burden in low- and middle-income countries and marked disparities in research infrastructure.
Moreover, proactive and diligent engagement with is indispensable for ensuring compliance and seamless , underscored by comparative research on and the adaptation of rigorous European Union standards to the Latin American context. Lastly, the integration of contemporary digital resources can significantly reinvigorate site monitoring and selection frameworks, supported by a growing commitment to improving healthcare outcomes, such as the collaborations by Mount Sinai and the Brazilian Clinical Research Institute. In sum, leveraging these tailored approaches can lead to more robust and efficacious clinical trials in the region.
References
, with a striking prevalence of disorders, bears a significant portion of the global disease burden. A staggering 80% of mental illness in low- and middle-income countries is present in this region, with low . For example, despite high levels of emotional distress reported in Ecuador, it allocates only 0.04% of its healthcare budget to , considerably lower than other n nations.
Moving to advancements in technology, the protection of in through regulations is in the spotlight due to increasing integration of artificial intelligence (AI). While some n countries draw inspiration from European models, areas needing enhancement are apparent, such as the urgent necessity for regulations specific to biometrics to prevent violations of privacy and security.
This highlights the importance of adapting , like the EU, to local n contexts to bolster data protection measures. Furthermore, embracing digital technology extends to healthcare research, with resources like PLOS working to connect experts and perspectives across disciplines, thereby addressing the multifaceted challenges in the field. The pursuit of such technologies and strategies in healthcare research is mirrored across other domains.
Notably, the concept of ‘digital twins,’ as explored in mathematical models, could revolutionize forecasting and modeling in various areas, including medicine.
Among authorities in the field, for advancing AI strategies and the management of research data in and the Caribbean. These collaborations are deemed crucial for harmonizing public policies and boosting joint efforts in . Stakeholders across 15 countries in the Americas actively participate in discussions, disclosing potential conflicts of interest to maintain the integrity of guidelines focused on improving healthcare practices, such as those for axial spondyloarthritis (axSpA), which cater to a broad spectrum of healthcare providers and patients.
In summary, confronting the crisis and securing are pivotal issues currently shaping ‘s approach to public healthcare and technological integration, drawing attention to the need for regional collaboration and the adoption of international best practices.
Conclusion
In conclusion, site selection in clinical trials plays a crucial role in determining the success and quality of the study. The integration of electronic health records (EHR) has the potential to revolutionize trials, but it requires careful consideration to effectively integrate EHR-sourced data into existing infrastructures. The modernization of platforms like ClinicalTrials.gov reflects the industry’s commitment to enhancing user engagement and operational efficiency.
Site selection in Latin America presents unique challenges due to cultural, linguistic, and logistical hurdles. Investigators must navigate the intricate regulatory landscape and address obstacles such as fragmented knowledge dissemination and regulatory convolutions. However, there are positive strides being made in the region, such as enhanced pharmacovigilance and training expansion, which create a more robust clinical trial environment.
Real-world case studies illustrate the importance of strategic site selection. Establishing partnerships with local investigators and research entities can address language and cultural barriers, as well as provide valuable insight into the nuanced regulatory environment. Leveraging technology, including data-driven approaches and historical trial data, optimizes site selection processes and improves patient demographics.
To enhance the success of future trials in Latin America, key recommendations include strengthening alliances with local investigators and academic bodies, engaging with regulatory bodies, and integrating contemporary digital resources. These tailored approaches can lead to more robust and efficacious clinical trials in the region.
Overall, strategic and inclusive site selection is crucial in clinical trials to ensure accurate data collection, operational success, and ultimately improve healthcare outcomes across Latin America.
Frequently Asked Questions
Why is site selection important in clinical trials?
Site selection is crucial as it directly influences patient recruitment, data quality, and adherence to timelines. Optimal site selection can enhance operational success and ensure data integrity.
How can electronic health records (EHR) impact clinical trials?
EHR can revolutionize clinical trials by providing valuable data that supplements traditional trial data. Effective integration of EHR with trial infrastructures is necessary to meet study objectives.
What are the challenges of conducting clinical trials in Latin America?
Challenges include navigating complex regulatory environments, addressing cultural and language differences, and managing logistical hurdles. Administrative delays and policy ambiguities can also impact trial procedures.
What role does patient-centricity play in clinical trial planning?
Patient-centricity emphasizes the importance of patient experiences in trial planning, advocating for inclusive approaches that accommodate diverse demographics and improve access to clinical trials.
What are the implications of diversity, equity, and inclusion (DEI) in clinical trials?
DEI is vital as it recognizes the varying impacts of diseases across different populations. Incorporating DEI into trial design enhances the relevance and effectiveness of studies.
How has technology improved clinical trial processes?
Technology, including real-time patient monitoring and data analytics, has expedited data collection and improved accuracy. The modernization of platforms like ClinicalTrials.gov also supports efficient trial management.
What is the significance of the DAPA-MI study in site selection?
The DAPA-MI study illustrates the innovative use of trial designs that blend registry and randomized control methodologies, emphasizing the importance of site infrastructure in enhancing patient enrollment and scientific clarity.
What are the regulatory challenges faced by clinical trials in Latin America?
Regulatory challenges include instability in health authorities, such as INVIMA in Colombia, and poor data conditions in Brazil, which complicate trial site selection and compliance.
How critical is the issue of mental health in clinical trials within Latin America?
Mental health is a significant concern, with the region carrying 80% of the global mental health disease burden. Increased focus on mental health trials is essential to address this crisis and improve healthcare outcomes.
What strategies can improve clinical trial success in Latin America?
Key strategies include forming partnerships with local researchers, engaging proactively with regulatory bodies, and utilizing digital resources to enhance site monitoring and selection processes.
What is the role of collaborative efforts in advancing clinical trials?
Collaborative efforts among stakeholders can harmonize public policies, enhance regulatory compliance, and improve data management, ultimately leading to more effective clinical trials.
How does the QuEST LAC network contribute to healthcare in Latin America?
The QuEST LAC network promotes high-quality care and research talent in Latin America, aiming to elevate healthcare standards and address the region’s pressing health challenges.
What can be learned from the partnership between Dana-Farber Cancer Institute and Oncoclínicas & Co?
This partnership exemplifies the importance of adopting best practices in oncology and emphasizes how high-quality site selection can lead to improved patient care and outcomes.
How do cultural and economic factors influence clinical trials in Latin America?
Cultural variances and economic conditions, particularly those related to industries like mining, can affect regulatory environments and the operationalization of clinical trial sites, impacting overall trial success.
What future developments are anticipated for clinical trials in Latin America?
Future developments may include more streamlined regulatory processes, enhanced training for investigators, and increased investment in digital tools to improve clinical trial efficiency and outcomes.
List of Sources
- Background
- trialsjournal.biomedcentral.com (https://trialsjournal.biomedcentral.com/counter/pdf/10.1186/s13063-023-07563-y)
- greenlight.guru (https://www.greenlight.guru/blog/selecting-a-site-for-your-clinical-trial)
- medhealthoutlook.com (https://medhealthoutlook.com/three-best-practices-to-combat-clinical-trial-pain-points-scott-gray-ceo-of-clincierge/)
- greenlight.guru (https://www.greenlight.guru/blog/how-to-set-up-clinical-studies-to-comply-with-us-fda-regulations)
- biztoc.com (https://biztoc.com/t/biomedicalresearch)
- nexus.od.nih.gov (https://nexus.od.nih.gov/all/2024/06/06/marking-a-milestone-the-modernized-clinicaltrials-gov-becomes-the-singular-website-experience/)
- biospace.com (https://www.biospace.com/article/treehill-partners-ali-pashazadeh-on-how-to-improve-clinical-trial-design/?utm_source=dlvr.it&utm_medium=twitter)
- appliedclinicaltrialsonline.com (https://www.appliedclinicaltrialsonline.com/view/scope-2024-alex-deyle-of-flatiron-health-discusses-rwd-in-clinical-trials)
- clinicaltrialsarena.com (https://www.clinicaltrialsarena.com/sponsored/why-patient-centricity-is-the-answer-to-the-clinical-trial-enrolment-gap/)
- Importance of Site Selection in Clinical Trials
- raps.org (https://www.raps.org/News-and-Articles/News-Articles/2024/1/Latin-America-Roundup-Argentina%E2%80%99s-president-names?utm_campaign=Regulatory-Focus&utm_source=twitter&utm_medium=social)
- trialsjournal.biomedcentral.com (https://trialsjournal.biomedcentral.com/counter/pdf/10.1186/s13063-023-07563-y)
- rethinkingclinicaltrials.org (https://rethinkingclinicaltrials.org/news/grand-rounds-june-14-2024-dapa-mi-a-pragmatic-registry-based-double-blind-rct-trial-designed-for-regulatory-evaluation-stefan-james-jonas-oldgren/)
- medhealthoutlook.com (https://medhealthoutlook.com/three-best-practices-to-combat-clinical-trial-pain-points-scott-gray-ceo-of-clincierge/)
- clinicaltrialsarena.com (https://www.clinicaltrialsarena.com/sponsored/why-patient-centricity-is-the-answer-to-the-clinical-trial-enrolment-gap/)
- innotechtoday.com (https://innotechtoday.com/how-tech-could-reshape-the-clinical-trial-process/)
- greenlight.guru (https://www.greenlight.guru/blog/selecting-a-site-for-your-clinical-trial)
- mckinsey.com (https://www.mckinsey.com/industries/life-sciences/our-insights/accelerating-clinical-trials-to-improve-biopharma-r-and-d-productivity)
- biospace.com (https://www.biospace.com/article/treehill-partners-ali-pashazadeh-on-how-to-improve-clinical-trial-design/?utm_source=dlvr.it&utm_medium=twitter)
- appliedclinicaltrialsonline.com (https://www.appliedclinicaltrialsonline.com/view/scope-2024-alex-deyle-of-flatiron-health-discusses-rwd-in-clinical-trials)
- Challenges in Site Selection in Latin America
- sciencedirect.com (https://www.sciencedirect.com/science/article/pii/S0301420723013363)
- sei.org (https://www.sei.org/features/wind-energu-wayuu-la-guajira/)
- nature.com (https://www.nature.com/articles/s41587-024-02274-4)
- rethinkingclinicaltrials.org (https://rethinkingclinicaltrials.org/news/grand-rounds-february-23-2024-virtual-vigilance-monitoring-of-decentralized-clinical-trials-adrian-hernandez-md-christopher-j-lindsell-phd/)
- fortrea.com (https://www.fortrea.com)
- raps.org (https://www.raps.org/News-and-Articles/News-Articles/2024/1/Latin-America-Roundup-Argentina%E2%80%99s-president-names?utm_campaign=Regulatory-Focus&utm_source=twitter&utm_medium=social)
- greenlight.guru (https://www.greenlight.guru/blog/how-to-set-up-clinical-studies-to-comply-with-us-fda-regulations)
- greenlight.guru (https://www.greenlight.guru/blog/data-management-and-reporting-in-fda-regulated-clinical-trials)
- greenlight.guru (https://www.greenlight.guru/blog/selecting-a-site-for-your-clinical-trial)
- Case Study Overview
- dana-farber.org (https://www.dana-farber.org/newsroom/news-releases/2023/first-international-collaborative-member-of-dana-farber-cancer-institute-opens-in-brazil-with-oncoclinicas-cancer-center?utm_source=twitter&utm_medium=social&utm_campaign=commark)
- raps.org (https://www.raps.org/News-and-Articles/News-Articles/2024/1/Latin-America-Roundup-Argentina%E2%80%99s-president-names?utm_campaign=Regulatory-Focus&utm_source=twitter&utm_medium=social)
- fortrea.com (https://www.fortrea.com)
- nature.com (https://www.nature.com/articles/s41591-024-03029-z)
- sciencedirect.com (https://www.sciencedirect.com/science/article/abs/pii/S0047272723001573)
- forum.effectivealtruism.org (https://forum.effectivealtruism.org/posts/mZK974Whp6cPoyqLM/the-relative-ethicalness-of-clinical-trial-designs)
- greenlight.guru (https://www.greenlight.guru/blog/selecting-a-site-for-your-clinical-trial)
- Methodology
- forum.effectivealtruism.org (https://forum.effectivealtruism.org/posts/MFRqdphhyddjgTwX4/vida-plena-transforming-mental-health-in-ecuador-first-year%7C)
- forum.effectivealtruism.org (https://forum.effectivealtruism.org/posts/ckeR258FkEmTWNZfu/enhancing-biometric-data-protection-in-latin-america-based)
- journals.sagepub.com (https://journals.sagepub.com/author-instructions/CTJ#ArticleTypes)
- forum.effectivealtruism.org (https://forum.effectivealtruism.org/posts/aQg5RG26CMsRneRYQ/doebem-s-research-methodology-for-evaluating-donation)
- raps.org (https://www.raps.org/News-and-Articles/News-Articles/2024/1/Latin-America-Roundup-Argentina%E2%80%99s-president-names?utm_campaign=Regulatory-Focus&utm_source=twitter&utm_medium=social)
- fortrea.com (https://www.fortrea.com)
- Results
- news-medical.net (https://www.news-medical.net/news/20230908/Mount-Sinai-and-BCRI-partner-to-improve-cardiovascular-health-and-education-in-Latin-America.aspx)
- infomeddnews.com (https://infomeddnews.com/annexin-pharmaceuticals-news-102523/)
- forum.effectivealtruism.org (https://forum.effectivealtruism.org/posts/MFRqdphhyddjgTwX4/vida-plena-transforming-mental-health-in-ecuador-first-year%7C)
- starfishmedical.com (https://starfishmedical.com/blog/voice-of-the-customer-medical-device-research-in-low-and-middle-income-countries/)
- fortrea.com (https://www.fortrea.com)
- siteselection.com (https://siteselection.com/issues/2024/jan/24-for-24.cfm)
- Discussion
- impact.economist.com (https://impact.economist.com/perspectives/health/one-stripe-time-raising-awareness-rare-diseases-latin-america)
- nature.com (https://www.nature.com/articles/s41587-024-02274-4)
- rethinkingclinicaltrials.org (https://rethinkingclinicaltrials.org/news/grand-rounds-february-23-2024-virtual-vigilance-monitoring-of-decentralized-clinical-trials-adrian-hernandez-md-christopher-j-lindsell-phd/)
- trialsjournal.biomedcentral.com (https://trialsjournal.biomedcentral.com/counter/pdf/10.1186/s13063-023-07578-5)
- onlinelibrary.wiley.com (https://onlinelibrary.wiley.com/doi/10.1111/jora.12951)
- theconversation.com (https://theconversation.com/whose-health-matters-the-diversity-deficit-in-clinical-trials-230196)
- raps.org (https://www.raps.org/News-and-Articles/News-Articles/2024/1/Latin-America-Roundup-Argentina%E2%80%99s-president-names?utm_campaign=Regulatory-Focus&utm_source=twitter&utm_medium=social)
- forum.effectivealtruism.org (https://forum.effectivealtruism.org/posts/MFRqdphhyddjgTwX4/vida-plena-transforming-mental-health-in-ecuador-first-year%7C)
- Recommendations for Future Trials
- cziscience.medium.com (https://cziscience.medium.com/request-for-information-accelerating-open-biomedical-research-in-latin-america-1d9145c7b13a)
- news-medical.net (https://www.news-medical.net/news/20230908/Mount-Sinai-and-BCRI-partner-to-improve-cardiovascular-health-and-education-in-Latin-America.aspx)
- news-medical.net (https://www.news-medical.net/news/20231110/NCI-grants-245-million-to-UTHealth-Houston-for-cancer-control-research-in-Mexico-and-Latin-America.aspx)
- pharmalive.com (https://www.pharmalive.com/ipg-health-launches-industrys-first-clinical-trial-diversity-offering/)
- fortrea.com (https://www.fortrea.com)
- starfishmedical.com (https://starfishmedical.com/blog/voice-of-the-customer-medical-device-research-in-low-and-middle-income-countries/)
- forum.effectivealtruism.org (https://forum.effectivealtruism.org/posts/MFRqdphhyddjgTwX4/vida-plena-transforming-mental-health-in-ecuador-first-year%7C)
- forum.effectivealtruism.org (https://forum.effectivealtruism.org/posts/ckeR258FkEmTWNZfu/enhancing-biometric-data-protection-in-latin-america-based)
- References
- speakingofmedicine.plos.org (https://speakingofmedicine.plos.org/2023/10/25/latest-medicine-healthcare-research/?utm_id=395&utm_source=twitter-x&utm_medium=social&utm_campaign=journals)
- biztoc.com (https://biztoc.com/t/biomedicalresearch)
- medium.com (https://medium.com/latinxinai/reinforcement-learning-from-human-feedback-rlhf-9d1d74040c1e)
- universityworldnews.com (https://www.universityworldnews.com/post.php?story=20240419182820349)
- forum.effectivealtruism.org (https://forum.effectivealtruism.org/posts/MFRqdphhyddjgTwX4/vida-plena-transforming-mental-health-in-ecuador-first-year%7C)
- nature.com (https://www.nature.com/articles/s41584-023-01034-z?utm_source=dlvr.it&utm_medium=twitter)
- forum.effectivealtruism.org (https://forum.effectivealtruism.org/posts/ckeR258FkEmTWNZfu/enhancing-biometric-data-protection-in-latin-america-based)
Leave a Reply